Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies.

about

Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies.

Item

http://www.wikidata.org/entity/Q50074012

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Approach to Richter transforma ...... in the era of novel therapies.

@en

Approach to Richter transforma ...... in the era of novel therapies.

@nl

type

Item

label

Approach to Richter transforma ...... in the era of novel therapies.

@en

Approach to Richter transforma ...... in the era of novel therapies.

@nl

prefLabel

Approach to Richter transforma ...... in the era of novel therapies.

@en

Approach to Richter transforma ...... in the era of novel therapies.

@nl

P1476

Approach to Richter transforma ...... in the era of novel therapies.

@en

P2093

Maliha Khan

http://www.w3.org/2001/XMLSchema#string

Philip A Thompson

http://www.w3.org/2001/XMLSchema#string

P2860

ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Richter's transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group.

P304

1-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-017-3149-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rabbia Siddiqi

P577

2017-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29063177

http://www.w3.org/2001/XMLSchema#string

P921

leukemia